238756-47-3 Usage
General Description
2-Chloroquinolin-6-amine is a chemical compound with the molecular formula C9H7ClN2. It is a chloro-substituted derivative of quinoline and is used as an intermediate in the synthesis of pharmaceutical compounds and agrochemicals. 2-Chloroquinolin-6-amine is a building block for a variety of heterocyclic compounds and has potential applications in the development of new drugs and pesticides. It is also known for its antiproliferative and cytotoxic properties, making it a valuable tool for biological research and drug discovery. Additionally, it is used in the preparation of fluorescent dyes and as a reagent in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 238756-47-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,8,7,5 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 238756-47:
(8*2)+(7*3)+(6*8)+(5*7)+(4*5)+(3*6)+(2*4)+(1*7)=173
173 % 10 = 3
So 238756-47-3 is a valid CAS Registry Number.
238756-47-3Relevant articles and documents
PICOLINAMIDE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES
-
Page/Page column 43-45, (2021/01/29)
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly in plants.
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
-
Page/Page column 18; 25-26, (2010/11/25)
Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
